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ABSTRACT 
Daunorubicin ((DNR)) used in oncological practice against a wide variety of solid organ tumors and hematologic malignancies, including 
leukemia, lymphoma, breast cancer, lung cancer, multiple myeloma and sarcoma. however clinical use of this agent is limited due to 
cardiomyopathy and cardiac heart failure. one of the important player in the development of cardic hypertrophy and reperfusion injury is renin-
angiotensin system. Aliskiren (ALK) a recent drug of a direct inhibitor of the renin enzyme. It Protect cardiomyopathy by the inhibition of the 
renin activity. Present study is towards the evaluation of protective effcets of ALK 50 and 100 mg/kg/day in rats. The systolic, diastolic, mean BP 
and heart rate were significantly (P< 0.01) increased in DNR control group as compared to normal control group. Thus the results provide clear 
evidence that the ALK pretreatment offered significant protection against DNR-induced Hemodynamic parameters changes.  
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INTRODUCTION  
Daunorubicin ((DNR)) has been used in oncological practice 
since the late 1960s. It is highly effective against a wide 
variety of solid organ tumors and hematologic malignancies, 
including leukemia, lymphoma, breast cancer, lung cancer, 
multiple myeloma and sarcoma1. The therapeutic use of this 
drug is restricted because of acute and chronic side effects 
especially in the heart and kidney. The acute side effects such 
as nausea, vomiting, sinus tachycardia and or ECG 
abnormalities such as non-specific ST-T wave changes. 
Tachyarrhythmias, including premature ventricular 
contractions, as well as heart block have also been reported 
associated with it. But the chronic side effects represented 
by the development of left ventricular ejection fraction 
(LVEF) and/or signs and symptoms of congestive heart 
failure (CHF) such as dyspnoea, pulmonary oedema, 
dependent oedema, cardiomegaly and hepatomegaly, 
oliguria, ascites, pleural effusion, and gallop rhythm2,3 .  
The exact mechanism of daunorubicn induced cardiotoxicity 
are unclear however data accumulated to date indicates that 
anthracycline metabolism either through generation of free 
radicals or toxic metabolites, or a combination of both, is a 
significant contributor to the drugs' cardiotoxicity4,5. This 
novel concept of cardiomyocyte apoptosis has broader 
implications, especially with regard to myocardial function, 
because loss of cardiomyocytes could initiate or exacerbate 
heart failure. in this pathway suggests that the drug-sensitive 
cells clinically relevant concentrations of DNR trigger then 
generation of ROS that leads to a process and makes the 
initial ROS burst the rate-limiting step in DNR-induced 
apoptosis signaling for the primary apoptotic initiation step6.  
Many types of agents have been used to treat DNR-induced 
cardiomyopathy including Quercetin, Pomegranate, Nigella 
Sativa Oil, Carvedilol, Talmisartan7,8,9,10. But, all of these 
agents have pronounced clinical disadvantages, including a 
significant decline in HDL levels, an inability to prevent DNR- 
induced mortality and weight loss, and potentiation of DNR- 
induced myelosuppression. Numerous studies have 
suggested that angiotensin-converting enzyme inhibitors 
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and angiotensin receptor blockers (ARBs) have protective 
effects against anthracycline cardiotoxicity11.   
The exact causal mechanism of DNR-induced 
cardiomyopathy is not completely clear. however, various 
mechanisms have been attributed to DNR-induced 
cardiomyopath such as release of vasoactive amines, 
generation of reactive oxygen species (ROS), induction of 
apoptosis, oxidative DNA damage, lipid peroxidation, 
impairment of enzymatic activity of creatine kinase, and 
induction of renin angiotensin system (RAS) activity12,13. The 
principal player involved in daunorubicin induced toxicity 
appears to be iron that catalyses the production of highly 
toxic hydroxyl radicals. it is also found that anthracycline 
inhibit iron mobilization from storage protein ferritin, 
resulting in accumulation of iron within the cardiomyocytes. 
topoisomerase II inhibition and DNA intercalation 
considered to play in antineoplastic effects while iron 
catalysed increased formation of ROS in anthracycline 
induced cardiotoxicity14,15.  
Anthracycline chemotherapeutic drugs as for 
example daunorubicin, adriamycin induced cardiomyopathy 
by involvement of over activity of cardiac renin angiotensin 
system. As reported previously also that Angiotensin II plays 
a important key role in the process of Anthracycline induced 
cardiotoxicity. The angiotensin-converting enzyme inhibitor 
and angiotensin receptor blocker play exert a protective role 
towards Anthracycline induced cardiotoxicity16,10,17.  
A novel drug of renin angiotensin system inhibitors aliskiren 
is a direct inhibitor of the renin enzyme and cardioprotective 
against Anthracyclineinduced toxicity in heart and kidney. In 
another way the inhibition of the renin activity by aliskiren 
may suitable and promising approach in the protection 
of Anthracycline induced toxicity18.  
MATERIALS AND METHODS 
Experimental animals 
The study synopsis was approved by the Institutional Animal 
Ethics Committee (IAEC) of Jaipur National University, Jaipur 
Rajasthan. Albino rats of Wistar strain, with body weight 
160–200 g were procured from Central Animal House 
Facility of Jaipur National University Jaipur and process 
under standard laboratory procedure conditions at 20–25 
8C. The animals were kept in propylene cages under 
controlled conditions of illumination and had a free access to 
commercial pellet diet and water ad libitum. 
Drugs and chemicals 
Daunorubicin (Jubilant Life sciences limited Bhartiagram 
Gajraula, Distt. Amroha UP), aliskiren (Dabur India Ltd., 
Sahibabad, Uttra Pradesh, India) and Telmisartan (Glenmark 
Pharmaceutical Ltd., Kisanpura, Himachal Pradesh) were 
gratefully received for the study. Caspase-3 inhibitor assay 
kits from BioVision (USA), LDH and CK-MB assay kits from 
Reckon Diagnostics Ltd. (India), were purchased. All the 
other chemicals used were of analytical grade. HPLC grade 
water was used for all biochemical assays. 
Experimental schedule 
After acclimatization, all the animals were randomly 
allocated into six groups of eight animals each and treated as 
follows: 
 Group I received physiological saline (0.5 mL/kg i.p., 
same schedule as group II) and served as control 
 Group II received Daunorubicin four times a week in 
sixteen equal doses over a period of four weeks for a 
cumulative dose of 1.25 mg/kg, i.p. 
 Groups III, IV, and V received 30 mg/kg ALK, 100 mg/kg 
ALK, 10 mg/kg Telmisartan respectively per day by oral 
for 42 days along with DNR (1.25 mg/kg, i.p.) as the 
same schedule as group II 
 Group VI received 100 mg/kg aliskiren alone by gavage 
for 42 days.  
After 24 h of last dose of DNR, the rats were anesthetized 
with ether for collection of blood samples from the tail vein. 
The hemodynamic parameters systolic blood pressure, 
diastolic blood pressure, mean arterial pressure and heart 
rate were measured 
Hemodynamic measurements 
Biopac Non-Invasive Blood Pressure Recording Instrument 
was used for Hemodynamic measurements by tail cuff 
method. All the rats were initially examined in the restrainer 
for a time of 15 min every day about 15 days before to the 
day of measurement of the hemodynamic parameters such 
as systolic blood pressure, diastolic blood pressure, mean 
blood pressure and heart rate. 
Data and statistical analysis 
All results are expressed as mean standard error of mean 
(S.E.M.). Groups of data are compared with the analysis of 
variance (Anova) followed by Dunnett’s t test to identify 
significance among groups. Values are considered 
statistically significant at P < 0.05.  
RESULTS 
Hemodynamic parameters 
The systolic, diastolic, mean BP and heart rate were 
significantly (P< 0.01) increased by 23.6%, 22.45%, 22.5% 
and 23% respectively in DNR control group as compared to 
normal control group. However, ALK 30, ALK 50, ALK 100 
and TEL 10 groups showed significant (P< 0.01) reduction in 
systolic (11.2%, 13.1%, 16.4% and 14.8% respectively), 
diastolic (9.2%, 11.5%, 16.0% and 14.0% respectively), 
mean arterial Pressure (10.05%, 12.14%, 16.16% and 
14.34% respectively) and heart rate (9.2%, 12.4%, 16.8% 
and 15.4% respectively) as compared to DNR control group. 
Although, ALK 30 pretreated group did not show significant 
protection from rise in hemodynamic parameters as 
compared to DNR control group 
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TABLE 1: 
Treatment 
regimen 
Systolic BP (mm Hg) Diastolic BP (mm Hg) Mean arterial Pressure 
(mm Hg) 
Heart rate (beats/min) 
Before 
Treatment 
After 
Treatment 
Before 
Treatment 
After 
Treatment 
Before 
Treatment 
After 
Treatment 
Before 
Treatment 
After 
Treatment 
Control  138.36  137.20 91.51  93.65 107.11  108.43 346.61  351.90 
DNR  137.12  169.55 95.06  114.68 108.97  132.83 345.82  432.84 
ALK (30mg/kg) 
+ DNR  
138.08  150.56 91.44  104.13 106.89 119.48 345.31  393.02 
ALK (50mg/kg) 
+ DNR 
137.85 147.51 94.4 101.49 108.77 116.71 355.60 379.17 
ALK (100 
mg/kg) + DNR  
137.96  141.75 94.6 96.33 108.94 111.36 357.52  360.13 
TEL (10mg/kg) 
+ DNR  
137.40  144.45 95.0  98.62 109.02  113.78 358.35  366.18 
ALK (100 
mg/kg)  
137.5  124.82 93.84  88.62 108.28 100.5 348.44  340.01 
 
 
Figure 1: Systolic blood pressure Vs. Treatment regimen 
Groups of data are compared with the analysis of variance (ANOVA) followed by Dunnett’s t test. 
Values are considered statistically significant at P < 0.05, p<0.01. DNR control compared with normal control group. p<0.01; All 
treated groups compared with DNR-control group 
ALK per se group compared with normal control group 
 
Figure 2: Diastolic blood pressure Vs. Treatment regimen 
Groups of data are compared with the analysis of variance (ANOVA) followed by Dunnett’s t test. 
Values are considered statistically significant at P < 0.05. p<0.01; DNR control compared with normal control group. p<0.05, 
p<0.01; All treated groups compared with DNR-control group. ALK per se group compared with normal control group 
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Figure 3: Mean arterial pressure Vs. Treatment regimen 
Groups of data are compared with the analysis of variance (ANOVA) followed by Dunnett’s t test. 
Values are considered statistically significant at P < 0.05. ##p<0.01; DNR control compared with normal control group. p<0.01; 
All treated groups compared with DNR-control group. ALK per se group compared with normal control group 
 
Figure 4: Heart rate Vs. Treatment regimen 
Groups of data are compared with the analysis of variance (ANOVA) followed by Dunnett’s t test. 
Values are considered statistically significant at P < 0.05. p<0.01; DNR control compared with normal control group. p<0.01; All 
treated groups compared with DNR-control group 
ALK per se group compared with normal control group 
DISCUSSION 
Daunorubicin is antibiotics belong to the anthracycline 
group widely used for for the treatment of cancer patients. 
The anticancer therapy with DNR is adversely limited by 
risks such as cardiomyopathy and congestive heart 
failure1,19. The pathogenesis of DNR-induced 
cardiomyopathy has not yet been fully clear but ongoing 
studies provides a good highlight to pathogenesis and give 
understanding to clear involvement of myocardial apoptosis 
and oxidative stress. In our findings we focused on studying 
the changes in apoptotic factor in terms of systolic blood 
pressure, diastolic blood pressure, mean arterial pressure 
and heart rate. The results of our study have fined that a 
sixteen equal cumulative doses of DNR (1.25 mg/kg, i.p.) 
induces cardiomyopathy in rats, which is similar with the 
previous reported studies by other investigators20,21. DNR 
administration caused a significant increase (P < 0.01) in the 
blood pressure; systolic, diastolic and mean, as well as heart 
rate in the pathogenic control rats (DNR) as compared to 
Normal control group which is in continuation to that of 
previous studies22,23. The increase in mean BP and heart rate 
in pathogenic rats as compared to normal healthy control 
rats could be the result of increased release of renin and 
catecholamines that leads to formation of Ang I and finally 
Ang II10. ALK prevented the increase in heart rate and blood 
pressure in this study and showed encouragement in its use 
as a antihypertensive drug and widely accepted as a key 
regulator of cardiovascular and renal function and plays a 
major role in water and salt homeostasis and blood pressure 
control. 
Through the inhibitory effect of renin activity by ALK in 
pretreatment significantly reduced systolic blood pressure, 
diastolic blood pressure, mean blood pressure and heart 
rate.  TEL pretreatment significantly decrease systolic blood 
pressure, diastolic blood pressure, mean blood pressure and 
heart rate by blocking angiotensin 1 receptor. The higher 
dose of ALK in treated rats showed better protection than 
TEL pretreated rats which may be because of inhibition of 
plasma renin activity by ALK24,25. It was found that ALK 30 
mg/kg, per day not effective in protecting DNR-induced 
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cardiomyocytes. This finding conclude that effect of ALK 30 
is blocked by DNR induced reactive stimulation of the renin-
angiotensin-aldosterone system and only higher dose of ALK 
could neutralize the renin-angiotensin-aldosterone 
system26,27.  
CONCLUSION 
On the basis of our above investigation it is recommended 
that DNR-induced cardiomyopathy has RAS relationship. The 
results find also indicate that ALK pretreatment may be an 
complement to weaken the DXR-induced cardiac toxic 
effects. Further studies are needed to validate this 
conclusion and find out the affiliation between DNR-induced 
cardiomyopathy and RAS. 
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